500024-95-3 Usage
Uses
Used in Organic Synthesis:
1-Boc-2-(N-hydroxycarbamimidoyl)pyrrolidine is used as a protecting group for amines in organic synthesis to prevent unwanted reactions from occurring at the amine functional group. This protection allows for selective reactions to take place elsewhere in the molecule, enhancing the efficiency and specificity of the synthesis process.
Used in Peptide and Drug Synthesis:
In the field of peptide and drug synthesis, 1-Boc-2-(N-hydroxycarbamimidoyl)pyrrolidine serves as a reagent, facilitating the formation of peptide bonds and contributing to the construction of complex molecular structures. Its presence aids in the synthesis of bioactive peptides and pharmaceutical compounds with desired therapeutic properties.
Used in Pharmaceutical Research:
1-Boc-2-(N-hydroxycarbamimidoyl)pyrrolidine is used as a starting material or intermediate in the development of new pharmaceutical agents. Its potential biological activities, such as anti-cancer and anti-inflammatory properties, make it a promising candidate for the discovery and design of novel therapeutic agents targeting various diseases and conditions.
Used in Medicinal Chemistry:
In medicinal chemistry, 1-Boc-2-(N-hydroxycarbamimidoyl)pyrrolidine is utilized for the exploration of its structure-activity relationships and optimization of its pharmacological properties. This research helps in understanding the compound's interaction with biological targets and its potential as a lead compound for drug development.
Overall, 1-Boc-2-(N-hydroxycarbamimidoyl)pyrrolidine is a multifaceted chemical with applications spanning across organic synthesis, peptide and drug synthesis, pharmaceutical research, and medicinal chemistry. Its versatility and potential biological activities make it an important compound in the development of new chemical entities and therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 500024-95-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,0,0,2 and 4 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 500024-95:
(8*5)+(7*0)+(6*0)+(5*0)+(4*2)+(3*4)+(2*9)+(1*5)=83
83 % 10 = 3
So 500024-95-3 is a valid CAS Registry Number.
InChI:InChI=1S/C10H19N3O3/c1-10(2,3)16-9(14)13-6-4-5-7(13)8(11)12-15/h7,15H,4-6H2,1-3H3,(H2,11,12)
500024-95-3Relevant academic research and scientific papers
LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS
-
Paragraph 0223; 0195; 0531, (2013/08/28)
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 and SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.
Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors
Pace, Paola,Di Francesco, M. Emilia,Gardelli, Cristina,Harper, Steven,Muraglia, Ester,Nizi, Emanuela,Orvieto, Federica,Petrocchi, Alessia,Poma, Marco,Rowley, Michael,Scarpelli, Rita,Laufer, Ralph,Paz, Odalys Gonzalez,Monteagudo, Edith,Bonelli, Fabio,Hazuda, Daria,Stillmock, Kara A.,Summa, Vincenzo
, p. 2225 - 2239 (2007/10/03)
Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.
